Assessing Productivity Loss and Activity Impairment in Severe or Difficult-to-Treat Asthma

Chen, Hubert; Blanc, Paul D.; Hayden, Mary Lou; Bleecker, Eugene R.; Chawla, Anita; Lee, June H.

doi:10.1111/j.1524-4733.2007.00229.x

Cited by 101 publications

(88 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The impact of asthma on patient QoL is substantial, and patients may be unable to perform normal daily activities [24,25]. Therefore, it is important to continuously assess asthma control, as it can fluctuate over time and patients with asthma that is not well controlled are at risk for deterioration [3].…”

Section: Discussionmentioning

confidence: 99%

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

Meltzer¹,

Kuna²,

Nolte³

et al. 2011

European Respiratory Journal

View full text Add to dashboard Cite

This study evaluated the effect of mometasone furoate (MF)/formoterol (F) versus its monocomponents, each administered via metered-dose inhaler, on asthma deteriorations and lung function.This 26-week, multicentre, double-blind, placebo-controlled study included subjects aged o12 yrs with not well-controlled asthma on low-dose inhaled corticosteroids. After a 2-3-week open-label runin (MF 100 mg b.i.d.), 746 subjects were randomised to receive placebo,

show abstract

Section: Discussionmentioning

confidence: 99%

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

Meltzer¹,

Kuna²,

Nolte³

et al. 2011

European Respiratory Journal

View full text Add to dashboard Cite

show abstract

“…conditions such as asthma or gastroesophageal reflux might affect workplace productivity. 8,9 Two existing measures, however, are generic self-report scales designed to be used with any health condition. Both the Work Productivity and Activity Impairment Questionnaire-Specific Health Problem (WPAI-SHP) 10 and the Stanford Presenteeism Scale 6 (SPS-6) 11 were designed such that a specific diagnosis can be substituted for ''problem'' or ''health problem'' on those scales.…”

Section: Introductionmentioning

confidence: 99%

Workplace Productivity and Voice Disorders: A Cognitive Interviewing Study on Presenteeism in Individuals With Spasmodic Dysphonia

Isetti

Meyer

2014

Journal of Voice

View full text Add to dashboard Cite

“…The validated tools included the 15-question Mini-Asthma Quality of Life Questionnaire (Mini-AQLQ), with scores ranging from 1 to 7 and higher scores indicating better quality of life 21 ; the 4-question Asthma Therapy Assessment Questionnaire (ATAQ), with scores ranging from 0 to 4 and higher scores indicating more control problems 22 ; and the 9-question Work Productivity and Activity Impairment (WPAI) questionnaire, with scores ranging from 0% to 100% and higher scores indicating greater impairment. [23][24][25] Proxies of asthma disease severity scales and adherence to controller medication regimens at the time of the survey were generated by using administrative claims data from the 12 months before the survey or the end of health plan eligibility, whichever came first. As was true for analyses of data from the retrospective cohort, both measures were controlled for in the multivariate analyses so that the independent association of controller medication with patient-reported outcomes could be determined.…”

Section: Survey Cohortmentioning

confidence: 99%

Impact of Asthma Controller Medications on Clinical, Economic, and Patient-Reported Outcomes

Tan

Sarawate

Singer

et al. 2009

Mayo Clinic Proceedings

View full text Add to dashboard Cite

OBJECTIVE:To comprehensively evaluate clinical, economic, and patient-reported outcomes associated with various therapeutic classes of asthma controller medications. PATIENTS AND METHODS:This observational study, which used administrative claims data from US commercial health plans, included patients with asthma aged 18 through 64 years who filled a prescription for at least 1 asthma controller medication from September 1, 2003, through August 31, 2005. Outcome metrics included the use of short-acting b-agonists (SABAs), the use of oral corticosteroids, inpatient (INP)/emergency department (ED) visits, and asthma-related health care costs. A subset of 5000 patients was randomly selected for a survey using the Mini-Asthma Quality of Life Questionnaire, the Work Productivity and Activity Impairment questionnaire, and the Asthma Therapy Assessment Questionnaire.RESULTS: Of 56,168 eligible patients, 823 returned completed questionnaires. Compared with inhaled corticosteroids (ICSs), leukotriene modifiers (LMs) were associated with lower odds of INP/ED visits (odds ratio [OR], 0.80; P<.001), lower odds of using 6 or more SABA canisters (OR, 0.81; P<.001), and higher annual cost ($193; P<.001). In the subgroup analysis of adherent patients, LMs were associated with higher odds of INP/ED visits (OR, 1.74; P=.04), lower odds of using 6 or more SABA canisters (OR, 0.46; P<.001), and higher annual cost ($235; P<.001). Inhaled corticosteroids and LMs had a comparable impact on all patient-reported outcomes. For combination therapy, ICS plus a long-acting b-agonist consistently showed at least equivalent or better outcomes in the use of SABAs and oral corticosteroids, the risk of INP/ED visits, cost, asthma control level, quality of life, and impairment in productivity and activity.CONCLUSION: Inhaled corticosteroids were associated with a lower risk of INP/ED visits, and a lower cost if adherence was achieved. When adherence cannot be achieved, LMs may be a reasonable alternative. Combination therapy with ICS plus a longacting b-agonist was associated with better or equivalent clinical, economic, and patient-reported outcomes.

show abstract

Assessing Productivity Loss and Activity Impairment in Severe or Difficult-to-Treat Asthma

Abstract: The WPAI:Asthma correlates with other self-reported asthma outcomes in the expected manner and predicts health-care utilization at 12 months when administered to patients with severe or difficult-to-treat asthma.

Cited by 101 publications

References 27 publications

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

Mometasone furoate/formoterol reduces asthma deteriorations and improves lung function

Workplace Productivity and Voice Disorders: A Cognitive Interviewing Study on Presenteeism in Individuals With Spasmodic Dysphonia

Impact of Asthma Controller Medications on Clinical, Economic, and Patient-Reported Outcomes

Contact Info

Product

Resources

About